Skip to main content

Mayo Clinic and Orion to Validate Breast Cancer Biomarkers

This correction clarifies that the alliance is to validate, not identify, breast cancer biomarkers.
 
NEW YORK (GenomeWeb News) — Orion Genomics will work with researchers at the Mayo Clinic to validate the company’s breast cancer screening technology in a clinical environment.
 
Orion will use its epigenetic biomarker-based technology with physicians at Mayo Clinic’s Department of Laboratory Medicine and Pathology to analyze cross-reactivity in more than a dozen types of breast cancer.
 
With epigenetic biomarkers, Orion said, it is developing tests to work in various tissues to enhance the capacity for early detection.
 
Its MethylScope platform can detect “methylation status of each and every human gene,” the company said, adding that it has already discovered more than 50 breast cancer biomarkers.
 
Orion has recently used its methylation platform to screen for colon cancer, cervical cancer, and other diseases at Washington University and at Johns Hopkins University Hospital.

The Scan

And For Adolescents

The US Food and Drug Administration has authorized the Pfizer-BioNTech SARS-CoV-2 vaccine for children between the ages of 12 and 15 years old.

Also of Concern to WHO

The Wall Street Journal reports that the World Health Organization has classified the SARS-CoV-2 variant B.1.617 as a "variant of concern."

Test for Them All

The New York Times reports on the development of combined tests for SARS-CoV-2 and other viruses like influenza.

PNAS Papers on Oral Microbiome Evolution, Snake Toxins, Transcription Factor Binding

In PNAS this week: evolution of oral microbiomes among hominids, comparative genomic analysis of snake toxins, and more.